JP2004528526A - 較正された遺伝子発現プロファイルを使用する生物学的状態又は作用因子を特徴付けするシステム及び方法 - Google Patents
較正された遺伝子発現プロファイルを使用する生物学的状態又は作用因子を特徴付けするシステム及び方法 Download PDFInfo
- Publication number
- JP2004528526A JP2004528526A JP2001528624A JP2001528624A JP2004528526A JP 2004528526 A JP2004528526 A JP 2004528526A JP 2001528624 A JP2001528624 A JP 2001528624A JP 2001528624 A JP2001528624 A JP 2001528624A JP 2004528526 A JP2004528526 A JP 2004528526A
- Authority
- JP
- Japan
- Prior art keywords
- panel
- subject
- profile data
- sample
- data set
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 217
- 230000014509 gene expression Effects 0.000 title claims description 95
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims abstract description 91
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 87
- 238000005259 measurement Methods 0.000 claims abstract description 54
- 235000018102 proteins Nutrition 0.000 claims abstract description 37
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 37
- 235000004252 protein component Nutrition 0.000 claims abstract description 25
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims abstract description 19
- 210000004027 cell Anatomy 0.000 claims description 184
- 239000000523 sample Substances 0.000 claims description 150
- 239000003795 chemical substances by application Substances 0.000 claims description 115
- 239000003814 drug Substances 0.000 claims description 88
- 239000008280 blood Substances 0.000 claims description 67
- 210000004369 blood Anatomy 0.000 claims description 66
- 150000001875 compounds Chemical class 0.000 claims description 63
- 230000000694 effects Effects 0.000 claims description 61
- 229940079593 drug Drugs 0.000 claims description 55
- 239000000203 mixture Substances 0.000 claims description 41
- 230000006870 function Effects 0.000 claims description 34
- 208000024891 symptom Diseases 0.000 claims description 34
- 238000003860 storage Methods 0.000 claims description 30
- 239000000047 product Substances 0.000 claims description 22
- 229940124597 therapeutic agent Drugs 0.000 claims description 22
- 230000004044 response Effects 0.000 claims description 21
- 238000012360 testing method Methods 0.000 claims description 21
- 230000008859 change Effects 0.000 claims description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 19
- 230000001225 therapeutic effect Effects 0.000 claims description 18
- 201000010099 disease Diseases 0.000 claims description 17
- 230000002757 inflammatory effect Effects 0.000 claims description 17
- 238000004458 analytical method Methods 0.000 claims description 14
- 206010061218 Inflammation Diseases 0.000 claims description 13
- 230000004054 inflammatory process Effects 0.000 claims description 13
- 231100000419 toxicity Toxicity 0.000 claims description 13
- 230000001988 toxicity Effects 0.000 claims description 13
- 230000004071 biological effect Effects 0.000 claims description 12
- 239000012530 fluid Substances 0.000 claims description 12
- 208000015181 infectious disease Diseases 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 12
- 230000002503 metabolic effect Effects 0.000 claims description 10
- 238000004590 computer program Methods 0.000 claims description 9
- 230000037213 diet Effects 0.000 claims description 9
- 235000005911 diet Nutrition 0.000 claims description 9
- 238000010195 expression analysis Methods 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 235000013376 functional food Nutrition 0.000 claims description 8
- 230000037081 physical activity Effects 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 210000000056 organ Anatomy 0.000 claims description 7
- 230000032683 aging Effects 0.000 claims description 6
- 210000001124 body fluid Anatomy 0.000 claims description 6
- 238000011156 evaluation Methods 0.000 claims description 6
- 239000012678 infectious agent Substances 0.000 claims description 6
- 230000010534 mechanism of action Effects 0.000 claims description 6
- 238000012544 monitoring process Methods 0.000 claims description 6
- 235000015097 nutrients Nutrition 0.000 claims description 6
- 239000000902 placebo Substances 0.000 claims description 6
- 229940068196 placebo Drugs 0.000 claims description 6
- 230000002588 toxic effect Effects 0.000 claims description 6
- 230000024245 cell differentiation Effects 0.000 claims description 5
- 230000010261 cell growth Effects 0.000 claims description 5
- 230000004962 physiological condition Effects 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 231100000331 toxic Toxicity 0.000 claims description 5
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 4
- 238000001574 biopsy Methods 0.000 claims description 4
- -1 cells Substances 0.000 claims description 4
- 230000007613 environmental effect Effects 0.000 claims description 4
- 210000000987 immune system Anatomy 0.000 claims description 4
- 230000007935 neutral effect Effects 0.000 claims description 4
- 238000011002 quantification Methods 0.000 claims description 4
- 238000007790 scraping Methods 0.000 claims description 4
- 230000002195 synergetic effect Effects 0.000 claims description 4
- 230000002485 urinary effect Effects 0.000 claims description 4
- 230000002792 vascular Effects 0.000 claims description 4
- 230000002411 adverse Effects 0.000 claims description 3
- 206010003246 arthritis Diseases 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 238000002372 labelling Methods 0.000 claims description 3
- 208000012239 Developmental disease Diseases 0.000 claims description 2
- 206010020751 Hypersensitivity Diseases 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims description 2
- 230000007815 allergy Effects 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 239000000470 constituent Substances 0.000 claims description 2
- 230000003054 hormonal effect Effects 0.000 claims description 2
- 230000007246 mechanism Effects 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 238000004445 quantitative analysis Methods 0.000 claims description 2
- 239000000376 reactant Substances 0.000 claims description 2
- 230000001850 reproductive effect Effects 0.000 claims description 2
- 230000000241 respiratory effect Effects 0.000 claims description 2
- 239000003053 toxin Substances 0.000 claims description 2
- 231100000765 toxin Toxicity 0.000 claims description 2
- 208000019553 vascular disease Diseases 0.000 claims description 2
- 230000003993 interaction Effects 0.000 claims 7
- 230000035790 physiological processes and functions Effects 0.000 claims 5
- 230000037396 body weight Effects 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000011159 matrix material Substances 0.000 claims 2
- 210000000653 nervous system Anatomy 0.000 claims 2
- 235000016709 nutrition Nutrition 0.000 claims 2
- 230000035764 nutrition Effects 0.000 claims 2
- 210000004994 reproductive system Anatomy 0.000 claims 2
- 210000002345 respiratory system Anatomy 0.000 claims 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims 1
- 239000013566 allergen Substances 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 230000001186 cumulative effect Effects 0.000 claims 1
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 239000002853 nucleic acid probe Substances 0.000 claims 1
- 230000001502 supplementing effect Effects 0.000 claims 1
- 238000005353 urine analysis Methods 0.000 claims 1
- 238000010586 diagram Methods 0.000 abstract description 9
- 239000002158 endotoxin Substances 0.000 description 60
- 229920006008 lipopolysaccharide Polymers 0.000 description 60
- 238000000338 in vitro Methods 0.000 description 53
- 238000011282 treatment Methods 0.000 description 32
- 230000000875 corresponding effect Effects 0.000 description 31
- 238000001727 in vivo Methods 0.000 description 24
- 235000014134 echinacea Nutrition 0.000 description 21
- 230000036541 health Effects 0.000 description 18
- 239000003550 marker Substances 0.000 description 17
- 241000258180 Echinacea <Echinodermata> Species 0.000 description 13
- 241000282414 Homo sapiens Species 0.000 description 13
- 230000009286 beneficial effect Effects 0.000 description 13
- 229960004584 methylprednisolone Drugs 0.000 description 12
- 230000000638 stimulation Effects 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 11
- 230000003321 amplification Effects 0.000 description 11
- 238000003199 nucleic acid amplification method Methods 0.000 description 11
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- 235000008216 herbs Nutrition 0.000 description 10
- 229960000485 methotrexate Drugs 0.000 description 10
- 239000002260 anti-inflammatory agent Substances 0.000 description 9
- 230000003110 anti-inflammatory effect Effects 0.000 description 9
- 244000133098 Echinacea angustifolia Species 0.000 description 8
- 229940121363 anti-inflammatory agent Drugs 0.000 description 8
- 238000013459 approach Methods 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 108020004999 messenger RNA Proteins 0.000 description 8
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 7
- 241000282412 Homo Species 0.000 description 7
- 102000000588 Interleukin-2 Human genes 0.000 description 7
- 108010002350 Interleukin-2 Proteins 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 108010047620 Phytohemagglutinins Proteins 0.000 description 7
- 241000295644 Staphylococcaceae Species 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 230000001885 phytohemagglutinin Effects 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 6
- 230000005856 abnormality Effects 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 229940013798 meclofenamate Drugs 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 150000007523 nucleic acids Chemical class 0.000 description 6
- 238000003908 quality control method Methods 0.000 description 6
- 239000000021 stimulant Substances 0.000 description 6
- 241001632410 Eleutherococcus senticosus Species 0.000 description 5
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 5
- 108010002616 Interleukin-5 Proteins 0.000 description 5
- 102100023132 Transcription factor Jun Human genes 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 102100040247 Tumor necrosis factor Human genes 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000010224 hepatic metabolism Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 101150071146 COX2 gene Proteins 0.000 description 4
- 101100114534 Caenorhabditis elegans ctc-2 gene Proteins 0.000 description 4
- 241000723353 Chrysanthemum Species 0.000 description 4
- 235000007516 Chrysanthemum Nutrition 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 101000998969 Homo sapiens Inositol-3-phosphate synthase 1 Proteins 0.000 description 4
- 102100036881 Inositol-3-phosphate synthase 1 Human genes 0.000 description 4
- 108090000978 Interleukin-4 Proteins 0.000 description 4
- 102000004388 Interleukin-4 Human genes 0.000 description 4
- 102000000743 Interleukin-5 Human genes 0.000 description 4
- 101150000187 PTGS2 gene Proteins 0.000 description 4
- 102100027584 Protein c-Fos Human genes 0.000 description 4
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 229940124599 anti-inflammatory drug Drugs 0.000 description 4
- 210000000601 blood cell Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 239000003246 corticosteroid Substances 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 229960003957 dexamethasone Drugs 0.000 description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000011223 gene expression profiling Methods 0.000 description 4
- 230000003308 immunostimulating effect Effects 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 101710163595 Chaperone protein DnaK Proteins 0.000 description 3
- 230000004544 DNA amplification Effects 0.000 description 3
- 102000016911 Deoxyribonucleases Human genes 0.000 description 3
- 108010053770 Deoxyribonucleases Proteins 0.000 description 3
- 206010013710 Drug interaction Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 description 3
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 description 3
- 101150085950 IL10 gene Proteins 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 3
- 102100037850 Interferon gamma Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000004891 communication Methods 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 229940000406 drug candidate Drugs 0.000 description 3
- 210000001508 eye Anatomy 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000003862 health status Effects 0.000 description 3
- 238000000099 in vitro assay Methods 0.000 description 3
- 239000000411 inducer Substances 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 229960005489 paracetamol Drugs 0.000 description 3
- 230000036515 potency Effects 0.000 description 3
- 229960005205 prednisolone Drugs 0.000 description 3
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 108020004463 18S ribosomal RNA Proteins 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 101000617823 Homo sapiens Solute carrier organic anion transporter family member 6A1 Proteins 0.000 description 2
- 101150083678 IL2 gene Proteins 0.000 description 2
- 102000004125 Interleukin-1alpha Human genes 0.000 description 2
- 108010082786 Interleukin-1alpha Proteins 0.000 description 2
- MQUQNUAYKLCRME-INIZCTEOSA-N N-tosyl-L-phenylalanyl chloromethyl ketone Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N[C@H](C(=O)CCl)CC1=CC=CC=C1 MQUQNUAYKLCRME-INIZCTEOSA-N 0.000 description 2
- 238000002944 PCR assay Methods 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 2
- 102000004495 STAT3 Transcription Factor Human genes 0.000 description 2
- 102100021991 Solute carrier organic anion transporter family member 6A1 Human genes 0.000 description 2
- 102000008221 Superoxide Dismutase-1 Human genes 0.000 description 2
- 108010021188 Superoxide Dismutase-1 Proteins 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- BFPSDSIWYFKGBC-UHFFFAOYSA-N chlorotrianisene Chemical compound C1=CC(OC)=CC=C1C(Cl)=C(C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 BFPSDSIWYFKGBC-UHFFFAOYSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000012631 diagnostic technique Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 231100000573 exposure to toxins Toxicity 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 208000027096 gram-negative bacterial infections Diseases 0.000 description 2
- 238000010874 in vitro model Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000009456 molecular mechanism Effects 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000005382 thermal cycling Methods 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 101150066838 12 gene Proteins 0.000 description 1
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
- 241000086254 Arnica montana Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 0 CCC*[C@](C)[C@](C)C[C@]1CC(C)CC1 Chemical compound CCC*[C@](C)[C@](C)C[C@]1CC(C)CC1 0.000 description 1
- 241000244203 Caenorhabditis elegans Species 0.000 description 1
- 101100496968 Caenorhabditis elegans ctc-1 gene Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 101150101999 IL6 gene Proteins 0.000 description 1
- 108700002232 Immediate-Early Genes Proteins 0.000 description 1
- 231100000750 In vitro toxicology Toxicity 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000014158 Interleukin-12 Subunit p40 Human genes 0.000 description 1
- 108010011429 Interleukin-12 Subunit p40 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 101100221647 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cox-1 gene Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 239000012807 PCR reagent Substances 0.000 description 1
- 101150062589 PTGS1 gene Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 238000012356 Product development Methods 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000009798 acute exacerbation Effects 0.000 description 1
- 238000011166 aliquoting Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 210000001691 amnion Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000009141 biological interaction Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 231100000392 biological toxicant Toxicity 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 230000001609 comparable effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013479 data entry Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000001819 effect on gene Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000007893 endotoxin activity Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 231100001238 environmental toxicant Toxicity 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000012826 global research Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 208000027136 gram-positive bacterial infections Diseases 0.000 description 1
- 210000000087 hemolymph Anatomy 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000004073 interleukin-2 production Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 238000012804 iterative process Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000000968 medical method and process Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 238000009206 nuclear medicine Methods 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 238000000275 quality assurance Methods 0.000 description 1
- 238000012372 quality testing Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229940124598 therapeutic candidate Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- 238000009602 toxicology test Methods 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 229940072651 tylenol Drugs 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Theoretical Computer Science (AREA)
- Medical Informatics (AREA)
- Evolutionary Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Zoology (AREA)
- General Physics & Mathematics (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14154299P | 1999-06-28 | 1999-06-28 | |
| US19552200P | 2000-04-07 | 2000-04-07 | |
| PCT/US2000/017846 WO2001025473A1 (en) | 1999-06-28 | 2000-06-28 | Systems and methods for characterizing a biological condition or agent using calibrated gene expression profiles |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004528526A true JP2004528526A (ja) | 2004-09-16 |
| JP2004528526A5 JP2004528526A5 (enExample) | 2010-09-24 |
Family
ID=26839213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001528624A Pending JP2004528526A (ja) | 1999-06-28 | 2000-06-28 | 較正された遺伝子発現プロファイルを使用する生物学的状態又は作用因子を特徴付けするシステム及び方法 |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1198585B1 (enExample) |
| JP (1) | JP2004528526A (enExample) |
| KR (1) | KR20020079364A (enExample) |
| AT (1) | ATE364721T1 (enExample) |
| AU (1) | AU784233B2 (enExample) |
| CA (1) | CA2378008A1 (enExample) |
| CY (1) | CY1107733T1 (enExample) |
| DE (1) | DE60035196T2 (enExample) |
| DK (1) | DK1198585T3 (enExample) |
| ES (1) | ES2290046T3 (enExample) |
| IL (2) | IL147349A0 (enExample) |
| PT (1) | PT1198585E (enExample) |
| WO (1) | WO2001025473A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7473528B2 (en) | 1999-01-06 | 2009-01-06 | Genenews Inc. | Method for the detection of Chagas disease related gene transcripts in blood |
| US6960439B2 (en) | 1999-06-28 | 2005-11-01 | Source Precision Medicine, Inc. | Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles |
| US7590493B2 (en) | 2000-07-31 | 2009-09-15 | Ocimum Biosolutions, Inc. | Methods for determining hepatotoxins |
| AUPR480901A0 (en) * | 2001-05-04 | 2001-05-31 | Genomics Research Partners Pty Ltd | Diagnostic method for assessing a condition of a performance animal |
| US7415358B2 (en) | 2001-05-22 | 2008-08-19 | Ocimum Biosolutions, Inc. | Molecular toxicology modeling |
| US6905827B2 (en) | 2001-06-08 | 2005-06-14 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases |
| US7235358B2 (en) | 2001-06-08 | 2007-06-26 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing and monitoring transplant rejection |
| US7026121B1 (en) | 2001-06-08 | 2006-04-11 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing and monitoring transplant rejection |
| US20030096264A1 (en) * | 2001-06-18 | 2003-05-22 | Psychiatric Genomics, Inc. | Multi-parameter high throughput screening assays (MPHTS) |
| US7447594B2 (en) | 2001-07-10 | 2008-11-04 | Ocimum Biosolutions, Inc. | Molecular cardiotoxicology modeling |
| AU2002365904A1 (en) * | 2001-07-10 | 2003-09-04 | Gene Logic, Inc. | Cardiotoxin molecular toxicology modeling |
| CA2457799C (en) | 2001-08-21 | 2014-05-27 | Ventana Medical Systems, Inc. | Method and quantification assay for determining c-kit/scf/pakt status |
| US6964850B2 (en) | 2001-11-09 | 2005-11-15 | Source Precision Medicine, Inc. | Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles |
| US7469185B2 (en) | 2002-02-04 | 2008-12-23 | Ocimum Biosolutions, Inc. | Primary rat hepatocyte toxicity modeling |
| AU2003272438B2 (en) | 2002-09-20 | 2009-04-02 | New England Biolabs, Inc. | Helicase dependent amplification of nucleic acids |
| US7662594B2 (en) | 2002-09-20 | 2010-02-16 | New England Biolabs, Inc. | Helicase-dependent amplification of RNA |
| AU2002952696A0 (en) * | 2002-11-14 | 2002-11-28 | Genomics Research Partners Pty Ltd | Status determination |
| US7778782B1 (en) | 2002-12-17 | 2010-08-17 | Entelos, Inc. | Peroxisome proliferation activated receptor alpha (PPARα) signatures |
| US7396645B1 (en) | 2002-12-17 | 2008-07-08 | Entelos, Inc. | Cholestasis signature |
| AU2003303238B2 (en) * | 2002-12-19 | 2010-07-22 | Life Technologies Corporation | Identification, monitoring and treatment of infectious disease and characterization of inflammatory conditions related to infectious disease using gene expression profiles |
| US7422854B1 (en) | 2002-12-20 | 2008-09-09 | Entelos, Inc. | Cholesterol reduction signature |
| US7519519B1 (en) | 2002-12-20 | 2009-04-14 | Entelos, Inc. | Signature projection score |
| AU2003901196A0 (en) * | 2003-03-17 | 2003-04-03 | Commonwealth Scientific And Industrial Research Organisation | Analysis method |
| EP2128270B1 (en) | 2003-08-08 | 2012-10-03 | Genenews Inc. | Osteoarthritis biomarkers and uses thereof |
| JPWO2005087924A1 (ja) * | 2004-02-18 | 2008-01-31 | 株式会社三重ティーエルオー | Ｄｎａチップ並びに疾患関連遺伝子の抽出方法 |
| WO2006138561A2 (en) | 2005-06-16 | 2006-12-28 | Source Mdx | Gene expression profiling for identification and monitoring of multiple sclerosis |
| AU2006294477A1 (en) | 2005-09-27 | 2007-04-05 | Source Mdx | Gene expression profiling for identification monitoring and treatment of rheumatoid arthritis |
| CA2652239A1 (en) * | 2006-05-16 | 2007-11-29 | Source Mdx | Assessment of effect of an agent on a human biological condition using rodent gene expression panels |
| US20100196889A1 (en) | 2006-11-13 | 2010-08-05 | Bankaitis-Davis Danute M | Gene Expression Profiling for Identification, Monitoring and Treatment of Colorectal Cancer |
| US20120009581A1 (en) | 2008-07-08 | 2012-01-12 | Bankaitis-Davis Danute M | Gene Expression Profiling for Predicting the Survivability of Prostate Cancer Subjects |
| CA2748823A1 (en) | 2009-01-06 | 2010-07-15 | Source Precision Medicine, Inc. D/B/A Source Mdx | Gene expression profiling for the identification, monitoring, and treatment of prostate cancer |
| US9074248B1 (en) | 2012-12-18 | 2015-07-07 | Qiagen Gmbh | Primers for helicase dependent amplification and their methods of use |
| CN103525926B (zh) * | 2013-10-08 | 2016-03-23 | 浙江大学 | 一种基于基因表达谱的药物毒性个体易感性基因标志物的筛选方法 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998024935A1 (en) * | 1996-12-06 | 1998-06-11 | Urocor, Inc. | Diagnosis of disease state using mrna profiles |
| WO1998031838A1 (en) * | 1997-01-15 | 1998-07-23 | Chugai Pharmaceutical Co., Ltd. | Method for analyzing quantitative expression of genes |
| WO1998039474A1 (en) * | 1997-03-04 | 1998-09-11 | Isis Innovation Limited | Non-invasive prenatal diagnosis |
| WO1999013113A1 (en) * | 1997-09-12 | 1999-03-18 | The Public Health Research Institute Of The City Of New York, Inc. | Non-competitive co-amplification methods |
| WO1999023254A1 (en) * | 1997-10-31 | 1999-05-14 | Affymetrix, Inc. | Expression profiles in adult and fetal organs |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5643765A (en) * | 1993-04-06 | 1997-07-01 | University Of Rochester | Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction |
| US5922184A (en) * | 1997-07-21 | 1999-07-13 | Bio-Rad Laboratories, Inc. | Computer-directed detection of paraproteins |
| AU9217198A (en) * | 1997-09-03 | 1999-03-22 | Oncormed | Method for predicting prognosis and treatment response for genetically based abnormalities |
-
2000
- 2000-06-28 DK DK00944977T patent/DK1198585T3/da active
- 2000-06-28 AU AU58985/00A patent/AU784233B2/en not_active Expired
- 2000-06-28 JP JP2001528624A patent/JP2004528526A/ja active Pending
- 2000-06-28 EP EP00944977A patent/EP1198585B1/en not_active Revoked
- 2000-06-28 WO PCT/US2000/017846 patent/WO2001025473A1/en not_active Ceased
- 2000-06-28 AT AT00944977T patent/ATE364721T1/de active
- 2000-06-28 KR KR1020017016828A patent/KR20020079364A/ko not_active Ceased
- 2000-06-28 DE DE60035196T patent/DE60035196T2/de not_active Revoked
- 2000-06-28 ES ES00944977T patent/ES2290046T3/es not_active Expired - Lifetime
- 2000-06-28 CA CA002378008A patent/CA2378008A1/en not_active Abandoned
- 2000-06-28 PT PT00944977T patent/PT1198585E/pt unknown
- 2000-06-28 IL IL14734900A patent/IL147349A0/xx unknown
-
2001
- 2001-12-26 IL IL147349A patent/IL147349A/en active IP Right Grant
-
2007
- 2007-09-12 CY CY20071101178T patent/CY1107733T1/el unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998024935A1 (en) * | 1996-12-06 | 1998-06-11 | Urocor, Inc. | Diagnosis of disease state using mrna profiles |
| WO1998031838A1 (en) * | 1997-01-15 | 1998-07-23 | Chugai Pharmaceutical Co., Ltd. | Method for analyzing quantitative expression of genes |
| WO1998039474A1 (en) * | 1997-03-04 | 1998-09-11 | Isis Innovation Limited | Non-invasive prenatal diagnosis |
| WO1999013113A1 (en) * | 1997-09-12 | 1999-03-18 | The Public Health Research Institute Of The City Of New York, Inc. | Non-competitive co-amplification methods |
| WO1999023254A1 (en) * | 1997-10-31 | 1999-05-14 | Affymetrix, Inc. | Expression profiles in adult and fetal organs |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1198585A1 (en) | 2002-04-24 |
| IL147349A0 (en) | 2002-08-14 |
| DE60035196T2 (de) | 2008-02-21 |
| EP1198585B1 (en) | 2007-06-13 |
| DE60035196D1 (de) | 2007-07-26 |
| AU5898500A (en) | 2001-05-10 |
| DK1198585T3 (da) | 2007-10-15 |
| ES2290046T3 (es) | 2008-02-16 |
| PT1198585E (pt) | 2007-09-20 |
| AU784233B2 (en) | 2006-02-23 |
| WO2001025473A1 (en) | 2001-04-12 |
| KR20020079364A (ko) | 2002-10-19 |
| IL147349A (en) | 2011-12-29 |
| WO2001025473A9 (en) | 2002-08-08 |
| ATE364721T1 (de) | 2007-07-15 |
| CY1107733T1 (el) | 2013-04-18 |
| CA2378008A1 (en) | 2001-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1198585B1 (en) | Method for characterizing a biological condition using calibrated gene expression profiles | |
| JP5236856B2 (ja) | 遺伝子発現プロファイルを用いる病気の同定、観測及び治療及び生物学的状態の同定 | |
| US6692916B2 (en) | Systems and methods for characterizing a biological condition or agent using precision gene expression profiles | |
| WO2008027428A2 (en) | Gene expression profiling for identification, monitoring and treatment of transplant rejection | |
| JP2005508505A5 (enExample) | ||
| JP2010227111A (ja) | 遺伝子発現プロフィールを用いる、感染症の同定、モニタリング、および処置、ならびに感染症に関連する炎症状態の特徴付け | |
| Baron et al. | Utilization of lymphoblastoid cell lines as a system for the molecular modeling of autism | |
| US20110306512A1 (en) | Gene Expression Profiling for Identification, Monitoring, and Treatment of Osteoarthritis | |
| AU2003303238A2 (en) | Identification, monitoring and treatment of infectious disease and characterization of inflammatory conditions related to infectious disease using gene expression profiles | |
| US20030175782A1 (en) | Genetic diagnosis/analysis apparatus and genetic diagnosis support system using the apparatus | |
| WO2008091708A2 (en) | Gene expression profiling for identification, monitoring, and treatment of lupus erythematosus | |
| JP2006510382A5 (enExample) | ||
| CN114333979A (zh) | 一种骨关节炎相关基因筛选与功能分析方法 | |
| WO2006138561A2 (en) | Gene expression profiling for identification and monitoring of multiple sclerosis | |
| Hoffman et al. | ATTACHMENT 3 STATISTICAL ANALYSIS OF TOXICOGENOMIC MICROARRAY DATA | |
| Jegga et al. | Microarray-based Gene Expression Analysis of Endocrine Systems: Principles of Experimental Design and Interpretation | |
| HK1169190A (en) | Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070628 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070628 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20070720 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20100324 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100330 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100617 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100624 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100730 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20100730 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110201 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110425 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110506 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110531 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110607 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110630 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120327 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20120424 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20120502 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20120426 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20120502 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20120502 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120626 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120704 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120720 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130129 |